Core Viewpoint - Aoxing Life Science Technology (06118) anticipates a significant profit increase for the fiscal year ending December 31, 2025, projecting a profit attributable to shareholders of no less than RMB 30 million, compared to approximately RMB 16 million for the fiscal year ending December 31, 2024 [1] Group 1: Profit Growth Drivers - The notable profit growth is primarily attributed to the company's focus on strategic efficiency measures, particularly the optimization of administrative management and research and development (R&D) expenditures, leading to a reduction in operating expenses [1] - An increase in other income, mainly from foreign exchange gains expected for the fiscal year ending December 31, 2025, also contributes to the profit growth [1] - A decrease in financial costs further supports the anticipated profit increase [1] Group 2: Operational Improvements - The optimization of administrative and R&D expenditures results from the company's proactive measures in organizational streamlining and operational excellence [1] - These measures reflect a more rigorous resource allocation and enhance financial flexibility, allowing the company to redirect resources towards strategic growth areas [1] - The initiatives not only demonstrate short-term profitability but also establish a sustainable development model for long-term value creation [1]